FDAsafety guidance72% confidence
Submitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of Drug
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Gilead.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Endocrinology · Type 2 Diabetes Mellitus
- Sub-indication
- General
Related signal: Gilead's GS-4571 Study Targets Safety and Pharmacokinetics in T2DM and Obesity